Publications by authors named "Ruoping Deng"

Although neoadjuvant chemotherapy (NAC) has become the standard treatment option for muscle invasive bladder carcinoma (MIBC), its application is still limited because of the lack of biomarkers for NAC prediction. We conducted a territory multicenter real-world study to summarize NAC practice in China and its associated clinicopathologic variables with NAC response. Then, we developed and validated a robust gene-based signature for accurate NAC prediction using weighted correlation network analysis (WGCNA), the least absolute shrinkage and selector operation (LASSO) algorithm, a multivariable binary logistic regression model, and immunohistochemistry (IHC).

View Article and Find Full Text PDF
Article Synopsis
  • - This study compares the effectiveness of three treatments for muscle-invasive bladder cancer (MIBC): neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and a combination of both.
  • - It finds that the neoadjuvant combination therapy has the best outcomes in terms of complete response rates and reducing the cancer stage, while also creating a model to predict which patients will benefit the most from this treatment.
  • - Additionally, it suggests that patients who fully respond to the treatments may be candidates for bladder preservation therapy, indicating a potential shift in how MIBC is treated.
View Article and Find Full Text PDF